Endothelial nitric oxide synthase is a key mediator of interleukin-2- induced hypotension and vascular leak syndrome

Journal of Immunotherapy

Volumn 34, Issue 5, 2011, Pages 419-427

  Samlowski, Wolfram E ^a   Kondapaneni, Muralidhar ^a   Tharkar, Shweta ^a   McGregor, John R ^a   Laubach, Victor E ^b   Salvemini, Daniela ^c  

^a NEVADA CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytokines; endothelial nitric oxide synthase; inducible nitric oxide synthase; interleukin 2 (IL 2); nitric oxide (NO)

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; METHYLENE BLUE; NITRIC OXIDE; PEROXYNITRITE; RECOMBINANT INTERLEUKIN 2; RNA; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME INHIBITION; HYPOTENSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANIMALS; BLOOD PRESSURE; CAPILLARY LEAK SYNDROME; CARCINOMA, RENAL CELL; CYCLIC GMP; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; HYPOTENSION; INTERLEUKIN-2; MELANOMA; METHYLENE BLUE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; ORGANOMETALLIC COMPOUNDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SUPEROXIDES;

EID: 79957922807     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31821dcb50     Document Type: Article

References (64)

1. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132. (Pubitemid 46606294)
2. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141. (Pubitemid 41702632)
3. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J Sci Am. 1997;3:S70-S72.
4. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116. (Pubitemid 29318842)
5. Samlowski WE, Wong B, Vogelzang NJ. Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. BJU Int. 2008;102:162-165. (Pubitemid 351852600)
6. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105:3041-3046. (Pubitemid 351723664)
7. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
8. Margolin KA, Rayner AA, Hawkins MA, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486-498. (Pubitemid 19098144)
9. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9: 694-704.
10. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7-20. (Pubitemid 19089076)
11. Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988;94:750-754.
12. Samlowski W, Petersen R, McGregor JR, et al. Evaluation of a superoxide dismutase mimetic as an adjunct to interleukin 2 based cancer therapy. In: Salvemini D, Cuzzocrea S, eds. Therapeutic Applications of Superoxide Dismutase. Austin: Landes Bioscience; 2004:1-22.
13. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med. 2004;2:17.
14. Hibbs JB Jr, Westenfelder C, Taintor R, et al. Evidence for cytokine inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992;89:867-877.
15. Ochoa JB, Curti B, Peitzman AB, et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst. 1992;84:864-867.
16. Kilbourn RG, Logothetis CJ, Striegel A, et al. NG-mono-methyl-L-arginine (NMA), an inhibitor of nitric oxide (NO.) production reverses interleukin-2 (IL-2) mediated hypotension in humans. Hypertension. 1993;1(suppl):s14.
17. Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med. 2003;9:750-755. (Pubitemid 36749225)
18. Samlowski WE, Yim C-Y, McGregor JR, et al. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J Immunother. 1995;18:166-178. (Pubitemid 26016522)
19. Irwan YY, Feng Y, Gach HM, et al. Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain. J Immunol Methods. 2009;349:45-55.
20. Kondapaneni M, McGregor J, Salvemini D, et al. Inducible nitric oxide synthase (iNOS) is not required for IL-2 induced hypotension and vascular leak syndrome in mice. J Immuno-ther. 2008;31:325-333. (Pubitemid 351595155)
21. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176-13181. (Pubitemid 26382789)
22. Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 1987;235:473-476. (Pubitemid 17009584)
23. Francis SH, Corbin JD. Progress in understanding the mechanism and function of cyclic GMP-dependent protein kinase. Adv Pharmacol. 1994;26:115-170.
24. Granger DL, Taintor RR, Boockvar KS, et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996; 268: 142-151. (Pubitemid 26286356)
25. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the l-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;851:51-70. (Pubitemid 46720134)
26. Gruetter CA, Barry BK, McNamara DB, et al. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res. 1979; 5:211-224. (Pubitemid 9246716)
27. Gelinas DS, Bernatchez PN, Rollin S, et al. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol. 2002; 137:1021-1030. (Pubitemid 35440742)
28. Hall CN, Garthwaite J. What is the real physiological NO concentration in vivo? Nitric Oxide. 2009;21:92-103.
29. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.
30. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768-770.
31. Stuehr DJ, Cho HJ, Kwon NS, et al. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD-and FMN-containing flavoprotein. Proc Natl Acad Sci USA. 1991;88:7773-7777. (Pubitemid 21915236)
32. Xie Q-W, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macro-phages. Science. 1992;256:225-228.
33. Forstermann U, Schmidt HH, Pollock JS, et al. Isoforms of nitric oxide synthase: characterization and purification from different cell types. Biochem Pharmacol. 1991;42:1849-1857.
34. Pollock JS, Forstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA. 1991;88: 10480-10484. (Pubitemid 21915859)
35. Bates TE, Loesch A, Burnstock G, et al. Immunocytochemical evidence for a mitochondrially located nitric oxide synthase in brain and liver. Biochem Biophys Res Commun. 1995;213: 896-900.
36. Ghafourifar P, Richter C. Nitric oxide synthase activity in mitochondria. FEBS Lett. 1997;418:291-296. (Pubitemid 27515942)
37. Furchgott RF, Zawadzki JV. The obligatory role of endothe-lial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376. (Pubitemid 11169009)
38. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265-9269.
39. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526. (Pubitemid 17085822)
40. Craven PA, DeRubertis FR. Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins: evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J Biol Chem. 1978;253:8433-8443. (Pubitemid 9082547)
41. Ignarro LJ, Degnan JN, Baricos WH, et al. Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta. 1982;718:49-59.
42. Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr Rev. 1994;15:135-162. (Pubitemid 24129181)
43. Quignard JF, Frapier JM, Harricane MC, et al. Voltage-gated calcium channel currents in human coronary myocytes: regulation by cyclic GMP and nitric oxide. J Clin Invest. 1997; 99:185-193. (Pubitemid 27053461)
44. Lincoln TM, Cornwell TL, Komalavilas P, et al. Cyclic GMP-dependent protein kinase in nitric oxide signaling. Methods Enzymol. 1996;269:149-166. (Pubitemid 26295704)
45. Hirata M, Murad F. Interrelationships of cyclic GMP, inositol phosphates and calcium. Adv Pharmacol. 1994;26:195-216.
46. Murad F. Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv Pharmacol. 1994;26:19-33.
47. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61-66. (Pubitemid 33769671)
48. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol. 1981;59:150-156. (Pubitemid 11152379)
49. Salvemini D, Mollace V, Pistelli A, et al. Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA. 1992;89:982-986.
50. Xia Y, Tsai AL, Berka V, et al. Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-depen-dent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998;273:25804-25808.
51. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22.
52. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun. 1993;18:195-199.
53. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
54. Vasquez-Vivar J, Santos AM, Junqueira VB, et al. Peroxy-nitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J. 1996;314(Pt 3):869-876. (Pubitemid 26097749)
55. Kossenjans W, Eis A, Sahay R, et al. Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclamp-sia. Am J Physiol Heart Circ Physiol. 2000;278:H1311-H1319. (Pubitemid 30235511)
56. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817-826. (Pubitemid 34263158)
57. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
58. Oelze M, Mollnau H, Hoffmann N, et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000;87:999-1005.
59. Gallagher DC, Bhatt RS, Parikh SM, et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res. 2007;13:2115-2120. (Pubitemid 46649880)
60. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005;314:738-744. (Pubitemid 41043857)
61. Connelly L, Madhani M, Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivo. J Biol Chem. 2005;280:10040-10046. (Pubitemid 40395855)
62. Cauwels A, Bultinck J, Brouckaert P. Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress. Cell Mol Life Sci. 2005;62:1632-1640. (Pubitemid 41021585)
63. Watson D, Grover R, Anzueto A, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004;32:13-20. (Pubitemid 38125558)
64. Kilbourn RG, Fonseca GA, Trissel LA, et al. Strategies to reduce side effects of interleukin-2: evaluation of the anti-hypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am. 2000; 6(suppl 1):S21-S30.